Trial Profile
Multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Oxycodone/naloxone (Primary)
- Indications Pain
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms PANDA
- Sponsors Mundipharma GmbH
- 20 Oct 2015 Results published in Mundipharma media release.
- 20 Oct 2015 Primary endpoint has not been met, as per Mundipharma media release.
- 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.